Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Fabhalta (iptacopan)
- lonafarnib
Interactions between your drugs
lonafarnib iptacopan
Applies to: lonafarnib, Fabhalta (iptacopan)
Iptacopan may reduce the blood levels of lonafarnib, which may make the medication less effective in some patients. Contact your doctor if your symptoms worsen or your condition changes. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
lonafarnib food
Applies to: lonafarnib
Lonafarnib should be taken with the morning and evening meals and an adequate amount of water. Do not consume grapefruit, grapefruit juice, or Seville oranges (also known as bitter or sour oranges).During treatment with lonafarnib. Juice from grapefruits and Seville oranges can increase the blood levels of lonafarnib. This may increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, loss of appetite, electrolyte (e.G., calcium, magnesium, potassium, phosphate, sodium) abnormalities, liver problems, low red and white blood cell counts, infection, and high blood pressure. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Filspari
Filspari is used to slow kidney function decline in adults with primary immunoglobulin A ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Pulmicort Turbuhaler
Pulmicort (budesonide) is used to prevent asthma attacks. Includes Pulmicort side effects ...
Entocort EC
Entocort EC is used to treat active, mild to moderate Crohn's disease (CD) that involves the ileum ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.